PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34158621-5	2021	Consistently, BACE1-null mice or mice treated with clinically tested BACE1 inhibitors Verubecestat and Lanabecestat exhibit severe reduction in hippocampal LTP and learning behaviors.	lanabecestat	103-115	beta-site APP cleaving enzyme 1	Mus musculus	14-19	
34158621-5	2021	Consistently, BACE1-null mice or mice treated with clinically tested BACE1 inhibitors Verubecestat and Lanabecestat exhibit severe reduction in hippocampal LTP and learning behaviors.	lanabecestat	103-115	beta-site APP cleaving enzyme 1	Mus musculus	69-74	
29181490-3	2017	As a potent BACE1 inhibitor, lanabecestat significantly reduced soluble Abeta species and soluble amyloid precursor proteins (sAPPbeta) in mouse, guinea pig, and dog in a time- and dose-dependent manner.	lanabecestat	29-41	beta-site APP cleaving enzyme 1	Mus musculus	12-17	
26890753-0	2016	AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.	lanabecestat	0-7	beta-site APP cleaving enzyme 1	Mus musculus	32-37	
26890753-3	2016	Here, we report the in vitro and in vivo pharmacological profile of AZD3293, a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics.	lanabecestat	68-75	beta-site APP cleaving enzyme 1	Mus musculus	159-164